Experts discuss Rebyota and the cost effectiveness of treating C. Difficile.
EP. 1: Burden of C. Difficile and Novel Therapies
Risks for sepsis and colectomy during the first twelve months of C. Difficile as well as additional burdens on the healthcare system. Novel therapies are also discussed.
EP. 2: Objectives of Cost Effective Analysis
Explanation of the cost-effectiveness analysis and additional factors involved when treating C. Difficile with REBYOTA.
EP. 3: Defining Standard of Care
Overview of Markov model, a tool used for calculating potential clinical outcomes and the associated costs, and its use in the REBYOTA study. The standard of care used in the study is also defined.
EP. 4: Target Population In Analysis
Brief rundown of patient demographics involved in REBYOTA trials and this cost-effectiveness analysis.
2 Clarke Drive Cranbury, NJ 08512